G D Roodman

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Biology of osteoclast activation in cancer
    G D Roodman
    University of Texas Health Science Center at San Antonio and Audie Murphy Veterans Administration Hospital, San Antonio, TX 78284, USA
    J Clin Oncol 19:3562-71. 2001
  2. ncbi request reprint Role of stromal-derived cytokines and growth factors in bone metastasis
    G David Roodman
    School of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Cancer 97:733-8. 2003
  3. ncbi request reprint Mechanisms of bone metastasis
    G David Roodman
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, School of Medicine Hematology, The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    N Engl J Med 350:1655-64. 2004
  4. ncbi request reprint Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand
    J H Han
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX 78284, USA
    Blood 97:3349-53. 2001
  5. ncbi request reprint Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts
    S V Reddy
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Endocrinology 142:2898-905. 2001
  6. ncbi request reprint Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma
    J C Cruz
    Department of Medicine, Texas Tech University, Lubbock, TX, USA
    Exp Hematol 29:441-7. 2001
  7. ncbi request reprint Cell biology of the osteoclast
    G D Roodman
    Department of Medicine, University of Texas Health Science Center, San Antonio, USA
    Exp Hematol 27:1229-41. 1999
  8. ncbi request reprint ADAM8: a novel osteoclast stimulating factor
    S J Choi
    Department of Medicine Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 16:814-22. 2001
  9. ncbi request reprint Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment
    S J Choi
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 16:1804-11. 2001
  10. doi request reprint Pathogenesis of myeloma bone disease
    G D Roodman
    Veterans Affairs Pittsburgh Healthcare System, Department of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15240, USA
    Leukemia 23:435-41. 2009

Collaborators

Detail Information

Publications72

  1. ncbi request reprint Biology of osteoclast activation in cancer
    G D Roodman
    University of Texas Health Science Center at San Antonio and Audie Murphy Veterans Administration Hospital, San Antonio, TX 78284, USA
    J Clin Oncol 19:3562-71. 2001
    ..Understanding of the molecular mechanisms responsible for osteoclast activation in osteolytic metastases should lead to development of novel therapeutic approaches for this highly morbid and potentially fatal complication of cancer...
  2. ncbi request reprint Role of stromal-derived cytokines and growth factors in bone metastasis
    G David Roodman
    School of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Cancer 97:733-8. 2003
    ..Bone is a storehouse of latent growth factors produced by stromal cells and osteoblasts that, when activated during osteoclastic bone resorption, can enhance the growth of tumor cells...
  3. ncbi request reprint Mechanisms of bone metastasis
    G David Roodman
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, School of Medicine Hematology, The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    N Engl J Med 350:1655-64. 2004
  4. ncbi request reprint Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand
    J H Han
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX 78284, USA
    Blood 97:3349-53. 2001
    ..Blood. 2001;97:3349-3353)..
  5. ncbi request reprint Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts
    S V Reddy
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Endocrinology 142:2898-905. 2001
    ....
  6. ncbi request reprint Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma
    J C Cruz
    Department of Medicine, Texas Tech University, Lubbock, TX, USA
    Exp Hematol 29:441-7. 2001
    ..These data demonstrate that early treatment of ARH-77 mice with IB prior to development of myeloma bone disease decreases OSA and possibly retards the development of lytic lesions, but not eventual tumor burden...
  7. ncbi request reprint Cell biology of the osteoclast
    G D Roodman
    Department of Medicine, University of Texas Health Science Center, San Antonio, USA
    Exp Hematol 27:1229-41. 1999
    ..The recent development of osteoclast cell lines may make it possible for major advances to our understanding of the biology of the osteoclast to be realized in the near future...
  8. ncbi request reprint ADAM8: a novel osteoclast stimulating factor
    S J Choi
    Department of Medicine Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 16:814-22. 2001
    ..Western blot analysis confirmed that the soluble form of ADAM8 is present in normal marrow cultures. These data suggest that ADAM8 plays an important role in OCL formation and acts primarily at the later stages of OCL differentiation...
  9. ncbi request reprint Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment
    S J Choi
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 16:1804-11. 2001
    ..These data show that the CTF of OIP-2, rather than the mature enzyme, mediates the inhibitory effects of OIP-2 through a putative receptor on OCL precursors...
  10. doi request reprint Pathogenesis of myeloma bone disease
    G D Roodman
    Veterans Affairs Pittsburgh Healthcare System, Department of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15240, USA
    Leukemia 23:435-41. 2009
    ..The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article...
  11. pmc Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures
    C Menaa
    Department of Medicine Hematology, University of Texas Health Science Center, San Antonio, Texas 78284, USA Audie Murphy Veterans Administration Hospital, San Antonio, Texas 78284, USA
    J Clin Invest 103:1605-13. 1999
    ..Taken together, these data suggest that AXII stimulates OCL formation by activating T cells through a putative receptor to secrete GM-CSF. GM-CSF then expands the OCL precursor pool to enhance OCL formation...
  12. ncbi request reprint Studies in Paget's disease and their relevance to oncology
    G D Roodman
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, USA
    Semin Oncol 28:15-21. 2001
    ..Paget's disease provides an ideal model in which to investigate the efficacy of the new third-generation bisphosphonates in the treatment of bone metastases as well as nonmalignant bone disease...
  13. pmc Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease
    S J Choi
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, Texas, USA
    J Clin Invest 108:1833-41. 2001
    ..These data support an important role for MIP-1alpha in cell homing, survival, and bone destruction in MM...
  14. ncbi request reprint A murine model of inflammatory bone disease
    T A Hentunen
    Department of Medicine Hematology, University of Texas Health Science Center, San Antonio, USA
    Bone 26:183-8. 2000
    ....
  15. pmc Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo
    J de la Mata
    Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA
    J Clin Invest 95:2846-52. 1995
    ..We conclude that IL-6 stimulatory effects on osteoclast precursors may enhance the effects of other bone resorption factors that act at later stages in the osteoclast lineage...
  16. ncbi request reprint Paget's disease of bone: a disease of the osteoclast
    S V Reddy
    Department of Medicine, Division of Hematology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX, USA
    Rev Endocr Metab Disord 2:195-201. 2001
    ..1). The basis for the abnormalities detected in Paget's disease and the role that the paramyxoviruses may play in this disease are still unclear...
  17. ncbi request reprint Myeloma bone disease
    N S Callander
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, USA
    Semin Hematol 38:276-85. 2001
    ..Treatment of myeloma bone disease includes radiation therapy, vertebroplasty, surgery, and bisphosphonates. New developments on the pathogenesis and treatment of myeloma bone disease present great opportunities to combat bone disease...
  18. ncbi request reprint Assignment of OSTF1 to human chromosome bands 12q24.1-->q24.2 by in situ hybridization
    R Schaub
    Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX 78284, USA
    Cytogenet Cell Genet 88:87-8. 2000
  19. ncbi request reprint Treatment strategies for bone disease
    G D Roodman
    Department of Medicine Hematology Oncology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA 15240, USA
    Bone Marrow Transplant 40:1139-46. 2007
    ..New therapies that can target both the tumor as well as the severe bone disease should be on the horizon to treat this devastating complication of myeloma...
  20. ncbi request reprint Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo
    H L Uy
    Department of Medicine, University of Texas Health Sciences Center, San Antonio 78284 7877, USA
    Cancer Res 57:3194-9. 1997
    ....
  21. ncbi request reprint Isolation and characterization of a cDNA clone encoding a novel peptide (OSF) that enhances osteoclast formation and bone resorption
    S Reddy
    Department of Medicine Hematology Endocrinology, the Veterans Administration Medical Center and The University of Texas Health Science Center, San Antonio, USA
    J Cell Physiol 177:636-45. 1998
    ....
  22. pmc Genetic linkage of Paget disease of the bone to chromosome 18q
    J D Cody
    Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284, USA
    Am J Hum Genet 61:1117-22. 1997
    ..40, with the genetic marker D18S42, a marker tightly linked to the FEO locus. This demonstrates that the gene(s) responsible for FEO and that for Paget disease are either closely linked or the same locus...
  23. ncbi request reprint Cloning and characterization of the 5'-flanking region of the mouse tartrate-resistant acid phosphatase gene
    S V Reddy
    Department of Medicine, University of Texas Health Science Center, San Antonio
    J Bone Miner Res 8:1263-70. 1993
    ..The availability of the TRAP promoter may also permit production of transgenic mice, which can be used to develop previously unavailable osteoclast cell lines...
  24. pmc Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease
    Noriyoshi Kurihara
    VA Pittsburgh Healthcare System, Research and Development, Pittsburgh, Pennsylvania 15240, USA
    J Clin Invest 117:133-42. 2007
    ....
  25. ncbi request reprint Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Lanie K Francis
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 12:6826-35. 2006
    ..Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on multiple myeloma cells...
  26. ncbi request reprint SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth
    Rentian Feng
    Division of Hematology Oncology, University of Pittsburgh Cancer Institute, PA 15232, USA
    Blood 109:2130-8. 2007
    ..We propose that SDX-308 is a promising therapeutic candidate to inhibit multiple myeloma growth and osteoclast activity and that it should receive attention for further study...
  27. pmc Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1
    Veronica Garcia-Palacios
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA, USA
    Bone 40:316-22. 2007
    ..Taken together, these results demonstrate that ECF-L enhances RANKL and 1,25-(OH)2D3-induced OCL formation by increasing adhesive interactions between OCL precursors through increased expression of ICAM-1 and LFA-1...
  28. pmc Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function
    Hongwei Rao
    Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 21:1657-65. 2006
    ..Antibody to alpha(9) inhibited OCL formation in human marrow cultures, and OCLs from alpha(9) knockout mice had a defect in actin ring reorganization and an impaired bone resorption capacity...
  29. pmc Chemokines in multiple myeloma
    Rohit Aggarwal
    Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA 15240, USA
    Exp Hematol 34:1289-95. 2006
    ....
  30. ncbi request reprint Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition
    Nicola Giuliani
    Cattedra e Unità Operativa UO di Ematologia Centro Trapianti Midollo Osseo CTMO, Universita degli Studi di Parma, Italy
    Blood 108:3992-6. 2006
    ..Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed...
  31. ncbi request reprint Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing ICAM-1 expression
    Veronica Garcia-Palacios
    Medicine Hematology Oncology 111 H, University Drive C, Pittsburgh, PA 15240, USA
    Ann N Y Acad Sci 1068:240-3. 2006
    ..Furthermore, ECF-L Fc did not enhance OCL formation by ICAM-1 knockout (KO) cells. Increased expression of ICAM-1 by ECF-L appears to be critical for its effects on OCL formation...
  32. ncbi request reprint Bone-breaking cancer treatment
    G David Roodman
    Nat Med 13:25-6. 2007
  33. ncbi request reprint Ultrastructure of bone cells in Paget's disease of bone
    Frederick R Singer
    John Wayne Cancer Institute, Santa Monica, California 90404, USA
    J Bone Miner Res 21:P51-4. 2006
  34. ncbi request reprint Experimental models of Paget's disease
    Noriyoshi Kurihara
    University of Pittsburgh, Department of Medicine Hematology Oncology, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 21:P55-7. 2006
    ..These mice developed abnormal OCLs and bone lesions similar to those found in Paget's patients. These results show that persistent expression of MVNP in OCLs can induce pagetic-like bone lesions in vivo...
  35. ncbi request reprint New potential targets for treating myeloma bone disease
    G David Roodman
    Department of Medicine Hematology Oncology, University of Pittsburgh and VA Pittsburgh Healthcare System, Medicine Hematology Oncology, Pittsburgh, Pennsylvania 15240, USA
    Clin Cancer Res 12:6270s-6273s. 2006
    ..The basis for both the increased bone destruction and decreased bone formation has been a topic of extensive investigation during the last several years...
  36. pmc 1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells
    Seiichi Ishizuka
    Teijin Institute for Bio Medical Research, Hino, Tokyo, Japan
    J Steroid Biochem Mol Biol 110:269-77. 2008
    ..In contrast, (23S)-25-deoxy-1alpha-hydroxyvitamin D(3)-26,23-lactone, which only blocks human VDR, these vitamin D antagonists can block VDR in human cells and rodent cells...
  37. pmc Bone building with bortezomib
    G David Roodman
    Office of Research and Development, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania 15240, USA
    J Clin Invest 118:462-4. 2008
    ....
  38. ncbi request reprint Pathophysiology of myeloma bone disease
    Flavia R Esteve
    University of Pittsburgh, Medicine Hematology Oncology, 5150 Centre Avenue, Pittsburgh, PA 15213, USA
    Best Pract Res Clin Haematol 20:613-24. 2007
    ..In addition, we also review the emerging data on novel targeted therapies aimed at ameliorating myeloma bone disease...
  39. ncbi request reprint Perspective on the osteoclast: an angiogenic cell?
    Frank C Cackowski
    University of Pittsburgh School of Medicine, Hematology Oncology, Pittsburgh, Pennsylvania, USA
    Ann N Y Acad Sci 1117:12-25. 2007
    ....
  40. ncbi request reprint Pathophysiology of multiple myeloma bone disease
    Suzanne Lentzsch
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, and Division of Hematology Oncology, Veterans Administration Pittsburgh Healthcare System, Research and Development, PA 15232, USA
    Hematol Oncol Clin North Am 21:1035-49, viii. 2007
    ..In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed...
  41. ncbi request reprint RANK ligand as a therapeutic target for bone metastases and multiple myeloma
    G David Roodman
    University of Pittsburgh School of Medicine and VA Medical Center, VA Pittsburgh Healthcare System, Research and Development 151 U, Pittsburgh, PA 15240, USA
    Cancer Treat Rev 34:92-101. 2008
    ..This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL...
  42. ncbi request reprint SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma
    Suzanne Lentzsch
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Pittsburgh, PA 15232, USA
    Arch Pharm (Weinheim) 340:511-6. 2007
    ..This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity...
  43. ncbi request reprint Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption
    Yi Lu
    Department of Medicine, University of Pittsburgh, University Drive, Pittsburgh, PA 15240, USA
    Cancer Res 67:3646-53. 2007
    ..This study may provide novel therapeutic targets for treatment of prostate cancer skeletal metastasis...
  44. ncbi request reprint Role of the microenvironment in multiple myeloma bone disease
    Alissa Huston
    University of Pittsburgh Cancer Institute, and VA Pittsburgh Healthcare System, Research and Development, PA 15240, USA
    Future Oncol 2:371-8. 2006
    ....
  45. ncbi request reprint Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation
    Aaron N Nguyen
    Scios Inc, 6500 Paseo Padre Parkway, Fremont, CA 94555, USA
    Exp Cell Res 312:1909-23. 2006
    ..Collectively, these results suggest that SCIO-469 treatment can suppress factors in the bone marrow microenvironment to inhibit MM cell proliferation and adhesion and also to alleviate osteolytic activation in MM...
  46. pmc Paget disease of bone
    G David Roodman
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15240, USA
    J Clin Invest 115:200-8. 2005
    ..In this review, the pathophysiology of PD and evidence for both a genetic and a viral etiology for PD will be discussed...
  47. ncbi request reprint (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease
    Seiichi Ishizuka
    Veterans Affairs Pittsburgh Healthcare System, Research and Development 151 U, University Drive, Pittsburgh, Pennsylvania 15240, USA
    Endocrinology 146:2023-30. 2005
    ..These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD...
  48. ncbi request reprint Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells
    Seiichi Ishizuka
    Department of Bone and Calcium Metabolism, Teijin Institute for Bio Medical Research, Hino, Tokyo, Japan
    J Steroid Biochem Mol Biol 89:331-4. 2004
    ..These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease...
  49. ncbi request reprint Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease
    Noriyoshi Kurihara
    Department of Medicine Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 19:1154-64. 2004
    ..TAF(II)-17 was in part responsible for the increased 1,25(OH)2D3 responsivity of pagetic OCL precursors...
  50. ncbi request reprint MIP-1 alpha and myeloma bone disease
    G David Roodman
    Bone Biology Center, University of Pittsburgh Medical Center, University of Pittsburgh, PA 15261, USA
    Cancer Treat Res 118:83-100. 2004
    ....
  51. ncbi request reprint Pathogenesis of myeloma bone disease
    G David Roodman
    Department of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Blood Cells Mol Dis 32:290-2. 2004
    ..This overview will focus on the factors recently identified that appear to play an important role in the bone destructive process in myeloma...
  52. ncbi request reprint Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells
    Jennifer L Roccisana
    Department of Medicine Division of Hematology, The University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 279:10500-7. 2004
    ..These data further suggest that HSF-2 is a downstream target of b-FGF to induce RANKL expression in stromal/osteoblast cells, and that HSF may play an important role in modulating RANKL gene expression in the bone microenvironment...
  53. ncbi request reprint IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
    Jun Won Lee
    Department of Medicine, Hematology Oncology Division, University of Pittsburgh, and Department of Vetrerans Affairs Medical Center, PA 15213, USA
    Blood 103:2308-15. 2004
    ..These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth...
  54. ncbi request reprint Role of the bone marrow microenvironment in multiple myeloma
    G David Roodman
    Center for Bone Biology, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pennsylvania 15261, USA
    J Bone Miner Res 17:1921-5. 2002
    ..In addition, potential therapeutic agents under investigation, which included RANKL antagonists, protein prenylation inhibitors, and osteoblast growth factors, were discussed...
  55. ncbi request reprint SV40 T antigen and telomerase are required to obtain immortalized human adult bone cells without loss of the differentiated phenotype
    Christian Darimont
    Nestle Research Center, 1000 Lausanne 26, Switzerland
    Cell Growth Differ 13:59-67. 2002
    ..These results demonstrate that reconstitution of telomerase activity in transformed SV40 T-antigen human osteoblast precursors or marrow stromal cells leads to the generation of immortalized cells with a preserved phenotype...
  56. ncbi request reprint MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
    Yasuo Oba
    Department of Medicine Hematology Oncology Division, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Exp Hematol 33:272-8. 2005
    ..Several chemokine receptors (CCR1, CCR5, and CCR9) mediate the effects of MIP-1alpha. In this study, we determined which of these mediates the effects of MIP-1alpha on human OCL formation and myeloma cells...
  57. ncbi request reprint The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma
    Lori A Ehrlich
    Department of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15240, USA
    Immunol Rev 208:252-66. 2005
    ..This article discusses the role of immune cells and inflammatory cytokines and chemokines in the increased OCL activity in PD and MM bone disease, as well as the potential role of interleukin-3 in the suppression of OBL activity in MM...
  58. ncbi request reprint Regulation of osteoclast differentiation
    G David Roodman
    University of Pittsburgh, School of Medicine Hematology Oncology, VA Pittsburgh Healthcare System, R and D 151 U, Room 2E 113, University Drive C, Pittsburgh, PA 15240, USA
    Ann N Y Acad Sci 1068:100-9. 2006
    ..OCL differentiation is controlled by exogenous hormones and cytokines as well as autocrine-paracrine factors that positively or negatively regulate OCL proliferation and differentiation...
  59. ncbi request reprint IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
    Lori A Ehrlich
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Blood 106:1407-14. 2005
    ..These data suggest that IL-3 plays a dual role in the bone destructive process in myeloma by both stimulating osteoclasts and indirectly inhibiting osteoblast formation...
  60. ncbi request reprint Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice
    Noriyoshi Kurihara
    Medicine Hem Onc, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 21:446-55. 2006
    ..These mice developed abnormal OCLs and bone lesions similar to those found in Paget's patients. These results show that persistent expression of MVNP in OCLs can induce pagetic-like bone lesions in vivo...
  61. ncbi request reprint Annexin II stimulates RANKL expression through MAPK
    Fanghong Li
    Department of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 20:1161-7. 2005
    ..Thus, both GM-CSF and RANKL are required for AX-II stimulation of OCL formation...
  62. ncbi request reprint Cloning and characterization of the annexin II receptor on human marrow stromal cells
    Ganwei Lu
    Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15240, USA
    J Biol Chem 281:30542-50. 2006
    ..Importantly, the annexin II receptor antibody dose-dependently blocked the stimulatory effects of annexin II on human osteoclast formation, demonstrating that the receptor mediates the effects of annexin II on osteoclast formation...
  63. ncbi request reprint Eosinophil chemotactic factor-L (ECF-L): a novel osteoclast stimulating factor
    Yasuo Oba
    Department of Medicine Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 18:1332-41. 2003
    ..ECF-L enhanced OCL formation without increasing RANKL levels. Anti-ECF-L inhibited RANKL-induced OCL formation. These results support a potent role of ECF-L in osteoclastogenesis...
  64. ncbi request reprint AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma
    Sun J Choi
    Department of Medicine Hematology Oncology, University of Pittsburgh, PA, USA
    Blood 101:3778-83. 2003
    ..The data suggest that strategies that enhance AML-1B expression or decrease AML-1A in MM cells may be beneficial therapeutically...
  65. ncbi request reprint Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer
    Raghavendra Vasudeva Murthy
    Department of Oncology, Institute of Biomedicine and Surgery, University of Linkoping, S 581 85 Linkoping, Sweden
    Clin Cancer Res 11:2293-9. 2005
    ..However, there is no study examining the relationship of legumain expression to clinocopathologic and biological variables in colorectal cancers...
  66. pmc Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
    Yazan Alsayed
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Department of Internal Medicine, University of Pittsburgh, PA, USA
    Blood 109:2708-17. 2007
    ..This study, therefore, demonstrates that SDF-1/CXCR4 is a critical regulator of MM homing and that it provides the framework for inhibitors of this pathway to be used in future clinical trials to abrogate MM trafficking...
  67. ncbi request reprint Myeloma bone disease: pathogenesis and treatment
    G David Roodman
    Center of Bone Biology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Oncology (Williston Park) 19:983-4, 986. 2005
    ..multiplemyeloma.org and are published on a regular basis in ONCOLOGY. For more information about the interactive series, see the MMRF ad on page 1089...
  68. ncbi request reprint High bone turnover markers predict poor outcome in patients with bone metastasis
    G David Roodman
    J Clin Oncol 23:4821-2. 2005
  69. ncbi request reprint Paget's disease-a VDR coactivator disease?
    Noriyoshi Kurihara
    Department of Medicine Hematology, University of Pittsburgh, Kaufmann Medical Building, Suite 601, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA
    J Steroid Biochem Mol Biol 89:321-5. 2004
    ....
  70. pmc Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference
    Allan Lipton
    Milton S Hershey Medical Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033 0850, USA, and Department of Oncology, Norwegian Radium Hospital, Oslo, Norway
    Clin Cancer Res 12:6209s-6212s. 2006
    ..The conclusions reached during the 2-day meeting are summarized in this article and presented in more detail in the individual articles and accompanying discussion sessions that comprise the conference proceedings...
  71. ncbi request reprint Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Alissa Huston
    Exp Hematol 34:1616. 2006
  72. ncbi request reprint Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease
    William E Friedrichs
    Department of Medicine Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 17:145-51. 2002
    ..These findings are consistent with the presence of a chronic MV infection in affected sites from these patients with Paget's disease...